RevM10 transduced hematopoietic stem cells(Systemix)(RevM10 transduced hematopoietic stem cells(Systemix))

概要

基本信息

药物类型

基因疗法

别名-

靶点-

作用机制

基因转移

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

非霍奇金淋巴瘤

原研机构

Systemix, Inc.

在研机构-

非在研机构

Systemix, Inc.

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 RevM10 transduced hematopoietic stem cells(Systemix) 相关的临床试验

NCT00003942 / Unknown status临床1/2期

A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support

RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of RevM10-treated stem cells plus chemotherapy and peripheral stem cell transplantation in treating patients who have HIV-related non-Hodgkin's lymphoma.

开始日期1998-11-01

申办/合作机构

Systemix, Inc.

[+1]

100 项与 RevM10 transduced hematopoietic stem cells(Systemix) 相关的临床结果

登录后查看更多信息

100 项与 RevM10 transduced hematopoietic stem cells(Systemix) 相关的转化医学

登录后查看更多信息

100 项与 RevM10 transduced hematopoietic stem cells(Systemix) 相关的专利（医药）

登录后查看更多信息

100 项与 RevM10 transduced hematopoietic stem cells(Systemix) 相关的药物交易

登录后查看更多信息